Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by mmarquison Mar 01, 2009 6:55pm
399 Views
Post# 15812514

RE: Odds and ends

RE: Odds and endsrjc,

Excellent post. Covers a lot of ground but very instructive for those new to BIO investing/SSS in particular.

I have been pondering the black-hole of where the FDA might be in deciding when or if we would be given approval to re-start.

I agree with your thoughts, which you've presented clearly, as usual. One event that I feel might inform this FDA quandry is the fact of TTH selling their whole stake. Not to say that TTH have any access to insider info, or even to the body language, from either SCT or the FDA but I consider that when TTH goes through the sort of analysis that you have done, they can bring all of their expert opinions to determining the probabalities about when and if FDA will give the go ahead. Assuming they can thus arrive at a higher level of confidence than we, mere investors, can muster I've concluded that they assessed the probability as relatively low, thus deciding to sell when they did.

They did wait until they could sell into a rising market, but I'm certain if they had a high probability of neart-term approval, coupled with the fact they must have been able to predict the positive impact on Stem-cell industry by the widely telegraphed Obama direction, they would have waited this 'short while' and made much more from their shares.

Regardless of this speculation I hope that 'something' positive will give us a big boost sooner than later. The 50% drop we suffered six months ago was said to be undeserved, but the longer it continues the more likely it's to become a self-fulfilling prophecy.

GLTL

MM
Bullboard Posts